What is the recommended tizanidine dosing for patients with chronic kidney disease, including recommendations for mild to moderate impairment (creatinine clearance ≥30 mL/min) and severe renal impairment (creatinine clearance <30 mL/min)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tizanidine Dosing in Chronic Kidney Disease

Tizanidine clearance is reduced by more than 50% in patients with severe renal impairment (creatinine clearance <25 mL/min), requiring cautious use with reduced individual doses rather than decreased dosing frequency. 1

Dosing Recommendations by Renal Function

Mild to Moderate Renal Impairment (CrCl ≥25-30 mL/min)

  • No specific dose adjustment is mandated in the FDA labeling for mild to moderate impairment
  • However, use with caution as pharmacokinetic changes begin at this level
  • Monitor closely for adverse effects (hypotension, sedation, dizziness, dry mouth) as indicators of drug accumulation 1

Severe Renal Impairment (CrCl <25 mL/min)

  • Reduce individual doses during titration rather than extending dosing intervals 1
  • Start at the lowest possible dose (2 mg) and titrate slowly
  • If higher total daily doses are needed, increase individual dose amounts rather than frequency 1
  • Maximum monitoring is essential: The prolonged drug effect duration necessitates close observation for hypotension, excessive sedation, and bradycardia 1

Critical Safety Considerations

Hypotension Risk

Tizanidine causes dose-related hypotension in two-thirds of patients at 8 mg doses, with peak effects at 2-3 hours post-dose 1. In renal impairment, this effect is prolonged and intensified due to reduced clearance. The risk of orthostatic hypotension and syncope increases substantially 1.

Hepatotoxicity Monitoring

Approximately 5% of patients develop transaminase elevations >3x upper limit of normal 1. Monitor ALT/AST at baseline and monthly for the first 6 months, particularly in CKD patients who may have altered drug metabolism 1.

QT Prolongation

Tizanidine blocks the rapid delayed rectifier potassium current (IKr), causing QT prolongation 2. This risk is amplified in renal impairment due to drug accumulation. Obtain baseline ECG and monitor for QTc changes, especially if combining with other QT-prolonging medications 2.

Practical Dosing Algorithm

For CrCl <25 mL/min:

  1. Start with 2 mg once daily (preferably at bedtime to minimize hypotension risk)
  2. Check blood pressure (supine and standing), heart rate, and assess sedation at 1-2 hours post-dose
  3. If tolerated after 3-7 days, may increase to 2 mg twice daily
  4. Subsequent increases: Add 2 mg to individual doses rather than adding doses (e.g., 4 mg twice daily before 2 mg three times daily)
  5. Avoid exceeding 8 mg per individual dose in severe renal impairment
  6. Monitor liver function tests monthly for 6 months, then quarterly

For CrCl 25-50 mL/min:

  • Standard titration may be used but with extended intervals between dose increases (5-7 days rather than 2-4 days)
  • Monitor for cumulative adverse effects more frequently than in patients with normal renal function

Common Pitfalls to Avoid

  • Do not use standard dosing schedules from the package insert without adjustment in severe CKD—the 50% reduction in clearance mandates dose modification 1
  • Avoid combining with other alpha-2 agonists (clonidine) or antihypertensives without careful blood pressure monitoring 1
  • Do not abruptly discontinue: Taper slowly to prevent rebound hypertension and tachycardia, which may be more severe in CKD 1
  • Women on oral contraceptives have 50% lower tizanidine clearance; this effect is additive to renal impairment, requiring even more conservative dosing 1

Drug Interactions in CKD

Avoid or use extreme caution with:

  • CYP1A2 inhibitors (ciprofloxacin, fluvoxamine): These dramatically increase tizanidine levels and proarrhythmic risk, particularly dangerous in CKD 2
  • Alcohol: Increases AUC by 20% and Cmax by 15%, with additive CNS depression 1
  • Other CNS depressants (baclofen, benzodiazepines): Additive sedation may mask signs of tizanidine toxicity 1

Monitoring Parameters

  • Blood pressure (supine and standing): Before each dose increase and at 1-2 hours post-dose
  • Heart rate: Watch for bradycardia, especially with beta-blockers
  • Renal function: Every 3-6 months or with clinical changes
  • Liver enzymes: Monthly for 6 months, then quarterly
  • Clinical assessment: Sedation level, muscle tone response, functional status

The limited long-term safety data at higher doses (>24 mg/day) combined with significantly reduced clearance in CKD makes conservative dosing mandatory 1. The goal is achieving spasticity control while avoiding the serious cardiovascular and hepatic complications that are amplified by renal impairment.

References

Related Questions

How should I adjust the flucytosine dose for a 70‑kg patient with chronic kidney disease and a creatinine clearance of 25 mL/min?
Can Chymoral Forte (pancreatin) be used in patients with chronic kidney disease, and what dosing and monitoring are recommended?
Can methocarbamol be used on an as-needed (PRN) basis in a patient with impaired renal function (GFR 38 mL/min), and what dose regimen is appropriate?
In a 51-year-old woman with a serum creatinine of 0.49 mg/dL, is her renal function normal and are any medication dose adjustments needed?
For a 60‑year‑old female weighing 53 kg with chronic kidney disease (creatinine 2.07 mg/dL, eGFR ≈ 27 mL/min) on prednisone 5 mg daily and currently using insulin glargine (Lantus) 18 U at 8 am with rapid‑acting insulin (ICR 11 U per 50 g carbohydrate), what should her insulin‑to‑carbohydrate ratio (ICR), insulin sensitivity factor (ISF), and basal insulin (Lantus) dose be?
What is the recommended meropenem dosing for a Klebsiella infection and what alternative agents should be used if the isolate is resistant to meropenem?
What is the drug of choice, with appropriate dosing and frequency, for managing hypertension in patients receiving capecitabine?
What is the recommended treatment for a patient with post‑traumatic stress disorder (PTSD) who also has paranoia?
What baseline and follow-up laboratory tests are recommended when starting mirtazapine (Remeron)?
Does meropenem (Merrem) provide adequate coverage for pneumonia in a patient already receiving it?
What is the recommended medication regimen after coronary artery bypass graft (CABG) surgery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.